Meeting
2014 Gastrointestinal Cancers Symposium
Prognostic and predictive value of tumor-infiltrating immune cells in Japanese patients with stage II/III gastric cancer.
Authors
Sophie Earle
Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, United Kingdom
Sophie Earle , Toru Aoyama , Alexander I. Wright , Darren Treanor , Yohei Miyagi , Lindsay C. Ward , Tomio Arai , Jeremy D. Hayden , Takaki Yoshikawa , Helene H. Thygesen , Heike I. Grabsch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 46)
DOI
10.1200/jco.2014.32.3_suppl.46
Abstract #
46
Poster Bd #
B20
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
First Author: Susanna Swoboda
Poster
2021 ASCO Annual Meeting
A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).
First Author: Olubukola Ayodele
Poster
2023 ASCO Breakthrough
Deciphering the tumor microenvironment (TME) dynamics in advanced colorectal (CRC) and pancreatic cancers (PDAC) treated with durvalumab (D) with olaparib (O) or cediranib (C): Results from a phase 2 randomized trial.
First Author: Alberto Hernando-Calvo